With only 2 active ingredients, the use of Scholar® and Bravatia® together ensures the control of post-harvest diseases in citrus fruit throughout the same campaign.
Scholar® was authorised in October for its use and marketing in citrus fruit post-harvest, with residues that are admitted in the United States, European Union countries, Switzerland, Norway, Australia and South Africa and in the CODEX, and it shows a high efficiency in preventing post-harvest diseases caused in citrus fruits by the fungi Penicilliumspp., Botrytisspp., Rhizopusspp., Colletotrichumspp….
The new product, based on fludioxonil, has been classified by the FRAC (Fungicide Resistance Action Committee) as not being very susceptible to generating resistances in fungal strains; it is low risk and it has no acute reference dose (ARfD); whilst retaining the important advantage of being very stable and for this reason, persistent throughout the commercial life of the citrus fruit.
The other product that complements the post-harvest treatment of citrus fruit is Bravatia®, the only authorised fungicide with a high efficiency to control Geotrichumcandidum and Penicilliumspp., based on propiconazole (belonging to the triazoles family), with residue that is admitted in the European Union, the United States, Canada, Switzerland and the CODEX, amongst others.
Trials have been carried out on mandarins, oranges, lemons and grapefruit, with the suitability of the treatment being corroborated for all the varieties analysed, at the same time as handling crossed resistances. The application of the treatment by drencher shower and by raft immersion, with 690ppm of Scholar® and 600 ppm of Bravatia® reduces infections by Penicillium spp. and Geotrichumcandidum in artificial inoculations by up to 90%; whilst in commercial conditions in the warehouse it reduces the infections caused by all of them by over 95%.
Production line application by spraying, in water or wax mixture, with a concentration of 2,880 ppm of Scholar® and 1,200 ppm of Bravatia® reduces infections against all the pathogens to over 85% in artificial inoculations and 95% in industrial conditions.
